Logomix
Logomix is accelerating the development of innovative regenerative medicine products through its unique iPSC genome engineering platform, Geno-Writing™. This platform is distinguished by its ability to perform rapid, precise, and megabase-scale modifications while minimizing spontaneous and off-target mutations. We also leverage this platform to develop sophisticated methods for obtaining high-yield differentiation into desired cell types. These capabilities drive both our internal program for type 1 diabetes and collaborative cell development projects with multiple partners.
